Health Insurance News Astrazeneca S Enhertu Breast Cancer Drug Added To China S State Insurance List
Search Related Content
Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Health Insurance News Astrazeneca S Enhertu Breast Cancer Drug Added To China S State Insurance List is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.Search RobinsPost News & Noticias
AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment
AstraZeneca and Daiichi Sankyo's drug Enhertu has shown strong results in two pivotal studies in the early stage of a certain type of breast cancer, according to data announced on Saturday. The ... Read More
AstraZeneca hails major breakthroughs with breast-cancer drugs
An executive at AstraZeneca says breast-cancer drugs that the company highlighted at an industry conference over the weekend could represent $10 billion worth of company sales in five years’ time. Read More
Enhertu pushes into early breast cancer, as antibody-drug conjugates move up the line
Enhertu can help patients with breast cancer when given earlier in the disease, according to data presented at the ESMO Conference 2025. Read More
ESMO: AZ, Daiichi unleash Enhertu's 2-fisted power, aiming to reshape early breast cancer landscape
AstraZeneca and Daiichi Sankyo’s star drug Enhertu has delivered a double knockout, showing its ability to stave off early breast cancer in two pivotal clinical trials. | AstraZeneca and Daiichi ... Read More
Astra, Daiichi post late-stage data to show Enhertu’s potential in early breast cancer
AstraZeneca (AZN) stock is in focus as the company and partner Daiichi (DSNKY) post trial data to show promise of Enhertu in early-stage breast cancer. Read more here. Read More
AstraZeneca's Datroway extends survival in aggressive breast cancer
Oct 19 (Reuters) - AstraZeneca (AZN.L) and Daiichi Sankyo's (4568.T) new breast cancer drug helped significantly extend survival in some patients in a late-stage trial, marking a potential ... Read More
Enhertu's Benefits in High-Risk Early-Stage Breast Cancer Come Into Focus in ESMO Data Readouts
The HER2-targeted ADC showed clear benefits over Roche's Kadcyla in the adjuvant setting, and promising activity versus standard neoadjuvant therapy. Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus